# Crexendo, Inc.: financial statements, quarterly

CXDO · Nasdaq · CIK 1075736 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cxdo.md) · [Financials](/companies/cxdo/financials.md) · [Filings](/companies/cxdo/filings.md) · [Insiders](/companies/cxdo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cxdo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.9](/filings/0001654954-24-013839.md) | [14.2](/filings/0001654954-24-002655.md) | [14.3](/filings/0001654954-25-005149.md) | [14.7](/filings/0001654954-25-009071.md) | [15.6](/filings/0001654954-25-012585.md) | [16.2](/filings/0001654954-26-001848.md) | [16.1](/filings/0001654954-26-004365.md) | [16.6](/filings/0001654954-26-007265.md) | [17.5](/filings/0001654954-25-012585.md) | [18.1](/filings/0001654954-26-001848.md) | [20.7](/filings/0001654954-26-004365.md) | [24.6](/filings/0001654954-26-007265.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.3](/filings/0001654954-25-002287.md) | [1.3](/filings/0001654954-25-002287.md) | [1.2](/filings/0001654954-26-001848.md) | [1.3](/filings/0001654954-26-001848.md) | [1.5](/filings/0001654954-26-001848.md) | [1.5](/filings/0001654954-26-001848.md) | [1.5](/filings/0001654954-26-004365.md) | [1.4](/filings/0001654954-26-007265.md) | [1.4](/filings/0001654954-26-001848.md) | [1.3](/filings/0001654954-26-001848.md) | [1.6](/filings/0001654954-26-004365.md) | [1.8](/filings/0001654954-26-007265.md) |
| Operating income | $m | [0.4](/filings/0001654954-25-002287.md) | [0.0](/filings/0001654954-25-002287.md) | [0.5](/filings/0001654954-26-001848.md) | [0.6](/filings/0001654954-26-001848.md) | [0.1](/filings/0001654954-26-001848.md) | [0.6](/filings/0001654954-26-001848.md) | [1.2](/filings/0001654954-26-004365.md) | [1.1](/filings/0001654954-26-007265.md) | [1.3](/filings/0001654954-26-001848.md) | [1.1](/filings/0001654954-26-001848.md) | [0.4](/filings/0001654954-26-004365.md) | [1.1](/filings/0001654954-26-007265.md) |
| Interest expense | $m | [0.0](/filings/0001654954-24-013839.md) | [0.0 d](/filings/0001654954-24-002655.md) | [0.0](/filings/0001654954-24-005696.md) | [0.0](/filings/0001654954-24-010039.md) | [0.0](/filings/0001654954-24-013839.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001654954-24-013839.md) | [0.0](/filings/0001654954-24-002655.md) | [0.0](/filings/0001654954-25-005149.md) | [0.0](/filings/0001654954-25-009071.md) | [0.0](/filings/0001654954-25-012585.md) | [0.1 d](/filings/0001654954-26-001848.md) | [0.0](/filings/0001654954-26-004365.md) | [0.0](/filings/0001654954-26-007265.md) | [0.0](/filings/0001654954-25-012585.md) | [0.2 d](/filings/0001654954-26-001848.md) | [0.0](/filings/0001654954-26-004365.md) | [0.0](/filings/0001654954-26-007265.md) |
| Net income | $m | [1.7](/filings/0001654954-25-002287.md) | [0.1](/filings/0001654954-25-002287.md) | [0.4](/filings/0001654954-26-001848.md) | [0.6](/filings/0001654954-26-001848.md) | [0.1](/filings/0001654954-26-001848.md) | [0.5](/filings/0001654954-26-001848.md) | [1.2](/filings/0001654954-26-007265.md) | [1.2](/filings/0001654954-26-007265.md) | [1.5](/filings/0001654954-26-001848.md) | [1.2](/filings/0001654954-26-001848.md) | [0.6](/filings/0001654954-26-007265.md) | [1.1](/filings/0001654954-26-007265.md) |
| Diluted EPS | $ per share | [0.06](/filings/0001654954-25-002287.md) | [0.00](/filings/0001654954-25-002287.md) | [0.01](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-001848.md) | [0.00](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-001848.md) | [0.04](/filings/0001654954-26-004365.md) | [0.04](/filings/0001654954-26-007265.md) | [0.05](/filings/0001654954-26-001848.md) | [0.04](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-004365.md) | [0.03](/filings/0001654954-26-007265.md) |
| Basic EPS | $ per share | [0.07](/filings/0001654954-25-002287.md) | [0.00](/filings/0001654954-25-002287.md) | [0.02](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-001848.md) | [0.01](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-001848.md) | [0.04](/filings/0001654954-26-004365.md) | [0.04](/filings/0001654954-26-007265.md) | [0.05](/filings/0001654954-26-001848.md) | [0.04](/filings/0001654954-26-001848.md) | [0.02](/filings/0001654954-26-004365.md) | [0.03](/filings/0001654954-26-007265.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [15.6](/filings/0001654954-23-014034.md) | [16.9](/filings/0001654954-25-002287.md) | [19.0](/filings/0001654954-24-005696.md) | [21.9](/filings/0001654954-24-010039.md) | [23.9](/filings/0001654954-24-013839.md) | [26.9](/filings/0001654954-26-001848.md) | [30.1](/filings/0001654954-25-005149.md) | [34.6](/filings/0001654954-25-009071.md) | [39.3](/filings/0001654954-25-012585.md) | [41.9](/filings/0001654954-26-007265.md) | [23.0](/filings/0001654954-26-004365.md) | [34.8](/filings/0001654954-26-007265.md) |
| Total assets | $m | [55.3](/filings/0001654954-23-014034.md) | [56.2](/filings/0001654954-25-002287.md) | [57.5](/filings/0001654954-24-005696.md) | [59.6](/filings/0001654954-24-010039.md) | [62.3](/filings/0001654954-24-013839.md) | [64.9](/filings/0001654954-26-001848.md) | [67.4](/filings/0001654954-25-005149.md) | [71.4](/filings/0001654954-25-009071.md) | [76.0](/filings/0001654954-25-012585.md) | [77.7](/filings/0001654954-26-007265.md) | [91.3](/filings/0001654954-26-004365.md) | [101](/filings/0001654954-26-007265.md) |
| Current liabilities | $m | [10.1](/filings/0001654954-23-014034.md) | [10.3](/filings/0001654954-25-002287.md) | [9.6](/filings/0001654954-24-005696.md) | [10.4](/filings/0001654954-24-010039.md) | [11.2](/filings/0001654954-24-013839.md) | [12.1](/filings/0001654954-26-001848.md) | [11.1](/filings/0001654954-25-005149.md) | [12.1](/filings/0001654954-25-009071.md) | [13.6](/filings/0001654954-25-012585.md) | [12.3](/filings/0001654954-26-007265.md) | [16.8](/filings/0001654954-26-004365.md) | [16.9](/filings/0001654954-26-007265.md) |
| Total liabilities | $m | [11.6](/filings/0001654954-23-014034.md) | [11.5](/filings/0001654954-25-002287.md) | [10.7](/filings/0001654954-24-005696.md) | [11.5](/filings/0001654954-24-010039.md) | [12.8](/filings/0001654954-24-013839.md) | [13.5](/filings/0001654954-26-001848.md) | [12.2](/filings/0001654954-25-005149.md) | [13.1](/filings/0001654954-25-009071.md) | [14.6](/filings/0001654954-25-012585.md) | [13.9](/filings/0001654954-26-007265.md) | [18.6](/filings/0001654954-26-004365.md) | [22.9](/filings/0001654954-26-007265.md) |
| Long-term debt | $m | [1.2](/filings/0001654954-23-014034.md) | not reported | [0.9](/filings/0001654954-24-005696.md) | [0.8](/filings/0001654954-24-010039.md) | [0.7](/filings/0001654954-24-013839.md) | [0.6](/filings/0001654954-25-002287.md) | [0.5](/filings/0001654954-25-005149.md) | [0.4](/filings/0001654954-25-009071.md) | [0.2](/filings/0001654954-25-012585.md) | [0.1](/filings/0001654954-26-001848.md) | not reported | not reported |
| Shareholders' equity | $m | [43.7](/filings/0001654954-24-013839.md) | [44.6](/filings/0001654954-26-001848.md) | [46.8](/filings/0001654954-25-012585.md) | [48.2](/filings/0001654954-25-012585.md) | [49.5](/filings/0001654954-25-012585.md) | [51.4](/filings/0001654954-26-007265.md) | [55.2](/filings/0001654954-26-007265.md) | [58.3](/filings/0001654954-26-007265.md) | [61.3](/filings/0001654954-25-012585.md) | [63.8](/filings/0001654954-26-007265.md) | [72.7](/filings/0001654954-26-007265.md) | [78.1](/filings/0001654954-26-007265.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,560 d](/filings/0001654954-24-013839.md) | [2,612 d](/filings/0001654954-25-002287.md) | [(166)](/filings/0001654954-25-005149.md) | [2,652 d](/filings/0001654954-25-009071.md) | [1,621 d](/filings/0001654954-25-012585.md) | [2,177 d](/filings/0001654954-26-001848.md) | [1,238](/filings/0001654954-26-004365.md) | [1,295 d](/filings/0001654954-26-007265.md) | [4,417 d](/filings/0001654954-25-012585.md) | [2,347 d](/filings/0001654954-26-001848.md) | [2,037](/filings/0001654954-26-004365.md) | [2,751 d](/filings/0001654954-26-007265.md) |
| Capital expenditure | $k | [1,459](/filings/0001654954-23-014034.md) | [0.0 d](/filings/0001654954-25-002287.md) | [0.0](/filings/0001654954-25-005149.md) | [0.0 d](/filings/0001654954-25-009071.md) | [0.0 d](/filings/0001654954-25-012585.md) | [27.0 d](/filings/0001654954-26-001848.md) | [0.0](/filings/0001654954-25-005149.md) | [18.0 d](/filings/0001654954-26-007265.md) | [0.0 d](/filings/0001654954-25-012585.md) | [0.0 d](/filings/0001654954-26-001848.md) | not reported | not reported |
| Dividends paid | $k | [0.0 d](/filings/0001654954-24-013839.md) | [0.0 d](/filings/0001654954-25-002287.md) | not reported | not reported | [0.0 d](/filings/0001654954-24-013839.md) | [0.0 d](/filings/0001654954-25-002287.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.6](/filings/0001654954-23-014034.md) | [25.7](/filings/0001654954-24-005696.md) | [26.0](/filings/0001654954-24-010039.md) | [27.7](/filings/0001654954-24-013839.md) | [30.1](/filings/0001654954-25-005149.md) | [29.5](/filings/0001654954-25-009071.md) | [29.9](/filings/0001654954-25-012585.md) | [31.1](/filings/0001654954-26-004365.md) | [31.3](/filings/0001654954-26-007265.md) | [31.8](/filings/0001654954-25-012585.md) | [32.7](/filings/0001654954-26-004365.md) | [34.2](/filings/0001654954-26-007265.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,253,790 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001654954-26-007265.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.